Business context and reporting period
Rhythm Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on rare genetic obesity. This Form 10-K reports the fiscal year ended December 31, 2020. Its lead product, IMCIVREE (setmelanotide), received FDA approval in November 2020 for chronic weight management in patients aged 6 and older with obesity caused by POMC, PCSK1, or LEPR deficiency confirmed by genetic testing. U.S. commercial availability was expected in the first quarter of 2021; the company reported no product sales revenue for 2020.
Financial performance and position
| Metric | 2020 | 2019 |
|---|---|---|
| Product revenue | $0 | $0 |
| Research and development expense | $90.5 million | $109.5 million |
| Selling, general and administrative expense | $46.1 million | $36.6 million |
| Total operating expenses | $136.6 million | $146.0 million |
| Net loss | $134.0 million | $140.7 million |
| Basic and diluted loss per share | $3.04 | $3.86 |
| Net cash used in operating activities | $122.0 million | $122.8 million |
With no product revenue, gross margin is not meaningful. R&D expense declined 17%, mainly following completion of several studies and lower sequencing activity; SG&A rose 26% amid commercial preparation, workforce costs, executive transition-related compensation, and compliance and market-access work. Net loss narrowed 5% year over year.
At December 31, 2020, cash and cash equivalents were $100.9 million and short-term investments were $71.9 million, totaling $172.8 million. Current assets were $181.7 million versus current liabilities of $18.0 million. Total liabilities were $20.5 million, including $3.1 million of lease liabilities; the filing reports no borrowing debt. Stockholders’ equity was $166.5 million and accumulated deficit was $459.3 million. No off-balance-sheet arrangements were reported.
Operating cash use was nearly unchanged from 2019. Investing activities provided $158.5 million, primarily from net maturities of short-term investments; financing activities provided $2.0 million, largely from option exercises and employee stock purchases. The company reported that the PRV sale and February 2021 stock offering generated approximately $260.1 million in combined net proceeds and expected available funds to support operations through at least the second half of 2023.
Material developments and outlook
- Regulatory and launch: The FDA approval made IMCIVREE the first approved therapy for the specified POMC, PCSK1, and LEPR deficiency obesities. The EU marketing application was under EMA review; management expected a decision and European launch in the second half of 2021.
- Clinical pipeline: The BBS/Alström Phase 3 trial met its primary and key secondary endpoints overall, but all primary-endpoint responders had BBS; none of the three Alström patients met the primary endpoint. Management planned BBS regulatory submissions in the second half of 2021 and further analysis to determine Alström next steps. January 2021 interim Phase 2 results in HET, SRC1, and SH2B1 cohorts were proof-of-concept data, not final results.
- Planned development: The company outlined potential Phase 3 work in HET, SRC1, and SH2B1 obesity, plus studies in hypothalamic obesity, younger children, additional MC4R-pathway genes, and a weekly formulation. Timelines were forward-looking and subject to regulatory discussions and trial progress.
- Capital and unusual items: The company sold its Rare Pediatric Disease Priority Review Voucher for $100 million, closing February 17, 2021, and completed a February 2021 offering of 5.75 million shares at $30 per share, with approximately $161.6 million net proceeds. These are post-year-end transactions and are not included in December 31, 2020 financial statements.
- Risks and contingencies: The company had a limited commercial history, no product-sales revenue, and expected continued operating losses. Key risks include reimbursement and market adoption, uncertain patient-population estimates, clinical and regulatory outcomes, COVID-19-related trial disruption, safety and tolerability, companion-diagnostic requirements, and reliance on third-party manufacturers. A post-marketing commitment to develop and validate a companion diagnostic remains; the partner’s FDA submission received a major deficiency letter. No material legal proceedings were reported.
- Audit and controls: Ernst & Young issued an unqualified opinion on the financial statements and internal control over financial reporting; management also concluded controls were effective at year-end.
Most important facts for investors to verify
- Whether IMCIVREE launch, patient identification, payer coverage, reimbursement, and commercial uptake translate into meaningful revenue.
- EMA review outcome and timing, and the status and final results of BBS and other setmelanotide trials, especially the limited Alström data.
- Progress resolving the companion-diagnostic deficiency and meeting the FDA post-marketing commitment.
- Whether the reported $260.1 million in post-year-end proceeds and the projected runway through at least the second half of 2023 remain adequate as spending and trial plans evolve.
- Manufacturing scale, supply continuity, and the impact of safety, competition, and rare-disease population uncertainty on commercialization prospects.